Disclosed are compounds of Formula I: and the pharmaceutically acceptable salts thereof, wherein “A” is S—; —SO—, —SO
2
—, —O— or NR
a-
, and R
a
, and R
1
through R
5
are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.
本发明涉及公式I的化合物及其药学上可接受的盐,其中“A”为S—;—SO—、—SO2—、—O或NRa-,Ra和R1至R5在此定义。本发明还涉及包含公式I化合物的制药配方以及通过抑制LRRK2激酶活性进行治疗、管理或改善可治疗、管理或改善的疾病的方法,例如帕
金森病。